- Integrated Diagnostics reported a rise in profit in the first nine months of the year as improved pricing and strong growth in patients served and tests performed.

For the first nine months of 2019, EBITDA (earnings) rose 27% to EGP 686m and revenues rose 20% to EGP 1.6bn.

The company also touted progress on a number of key strategic initiatives, including the continued rollout of new branches in Nigeria and the launch of its new healthcare management services venture Wayak, which deployed data mining and artificial intelligence platforms.

'Management remains confident as regards to its full-year targets and I look forward to reporting in the months ahead on yet another year of operational excellence and strong financial performance,' said Integrated Diagnostics.

At 9:58am: [LON:IDHC] Integrated Diagnostics Holdings Plc share price was -0.05p at 4.55p

Story provided by